From Our Perspective
Insights from CDER leadership and experts on public health actions
FDA actions to continue to ensure the safety of the nation’s drug supply
By Dr. Patrizia Cavazzoni, Director, FDA Center for Drug Evaluation and Research
One of FDA’s top priorities is ensuring the safety, quality, and effectiveness of the drug products available to the American public. Manufacturers of drugs intended for the U.S. market, including over-the-counter monograph drug products, are obligated to ensure that their products comply with Current Good Manufacturing Practice (CGMP) requirements and appropriate quality specifications.
More with Patrizia Cavazzoni, M.D.